Αρχική World News EMA Recommends Granting a Conditional Marketing Authorisation for Avapritinib

EMA Recommends Granting a Conditional Marketing Authorisation for Avapritinib

On 23 July 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a conditional marketing authorisation for the medicinal product avapritinib (Ayvakyt), intended for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor (PDGFR) alpha D842V mutation.

The applicant for this medicinal product is Blueprint Medicines (Netherlands) B.V.

Ayvakyt will be available as film-coated tablets (100 mg, 200 mg and 300 mg). The active substance of Ayvakyt is avapritinib, a protein kinase inhibitor (ATC code: L01EX18) designed to potently and selectively inhibit oncogenic KIT and PDGFR alpha mutants by targeting the active conformation of the kinase.

The benefits with Ayvakyt are its ability to provide durable responses in patients with GIST harbouring the PDGFR alpha D842V mutation.

The most common side effects (in ≥20% of patients) are nausea, fatigue, anaemia, periorbital oedema, face oedema, hyperbilirubinaemia, diarrhoea, vomiting, oedema peripheral, lacrimation increased, decreased appetite and memory impairment.

The full indication is:

AYVAKYT is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic GIST harbouring the PDGFR alpha D842V mutation.

It is proposed that Ayvakyt be prescribed by physicians experienced in the treatment of anticancer therapy.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

Summaries of positive opinion are published without prejudice to the European Commission decision, which will normally be issued 67 days from adoption of the opinion.

A conditional marketing authorisation is granted to a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. The marketing authorisation holder is likely to provide comprehensive clinical data at a later stage.

This product was designated as orphan medicine during its development. EMA will now review the information available to date to determine if the orphan designation can be maintained.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

An existing blood test for ovarian cancer has been re-evaluated. The results are in.

Ovarian cancer is the sixth most common cancer in women in the UK, with about 7,400 new cases every year. This number equates to...

How to Stay Healthy After Cancer

I try to pack helpful advice into every follow-up visit I have with patients, focusing on little tips that help foster healthy lifestyles. This...

Feasibility and Preliminary Efficacy Results of the Beat AML Study

Precision medicine in acute myeloid leukaemia (AML) is feasible in terms of providing cytogenetic and mutational data within 7 days, allowing their rapid incorporation into...

Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy

When she was six months pregnant, Desiree Doughty noticed that something seemed to be wrong with her breasts. “I noticed that one of my breasts...

Pumpkin Season!

Halloween may look different this year but we can still decorate our homes and enjoy a favorite fall treat – pumpkin and pumpkin seeds....

ACHIEVE-2 Results of Oxaliplatin-Based Adjuvant Chemotherapy in Asian Patients with High-Risk Stage II Colon Cancer

The Asian researchers reported on 25 October 2020 in the Annals of Oncology that 3-month of combination therapy for adjuvant treatment of high-risk stage...